[go: up one dir, main page]

US4073687A - Enzymatic acylation to afford β-lactam antibiotics - Google Patents

Enzymatic acylation to afford β-lactam antibiotics Download PDF

Info

Publication number
US4073687A
US4073687A US05/686,219 US68621976A US4073687A US 4073687 A US4073687 A US 4073687A US 68621976 A US68621976 A US 68621976A US 4073687 A US4073687 A US 4073687A
Authority
US
United States
Prior art keywords
acid
process according
amino acid
mycelium
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/686,219
Inventor
Eiji Kondo
Takashi Mitsugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of US4073687A publication Critical patent/US4073687A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C12P35/04Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin by acylation of the substituent in the 7 position
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/911Microorganisms using fungi
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/911Microorganisms using fungi
    • Y10S435/925Cephalosporium

Definitions

  • This invention relates to a process for preparing penicillin or cephalosporin antibiotics represented by the following formula: ##STR4## where ##STR5## is an acyl group derived from an ⁇ -amino acid, N-ammonium salt of ⁇ -amino acid, or N-(C 1 to C 10 ) acyl- ⁇ -amino acid; COOM is a carboxy or carboxylate salt group!
  • an amino compound selected from the group consisting of 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid and their salts By treating an amino compound selected from the group consisting of 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid and their salts, with an ester represented by the following formula:
  • R 1 is a (C 1 to C 10 ) alkyl group! by enzymatic acylation effected with mycelium or mycelium preparation from a microorganism belonging to genus Aphanocladium or Cephalosporium.
  • amino compounds include 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid, and their salts.
  • the salts are those at the carboxyl group, including such salts as alkali metal salts, alkaline earth metal salts, and tertiary amine salts; and those at the amino group, including such mineral acid salts as hydrochloride, hydrogen sulfate, and hydrogen carbonate.
  • Preferable salts are alkali metal salts at the carboxy group.
  • the said amino acid can be glycine, phenylglycine, cyclohexadienylglycine, cyclohexylglycine, thienylglycine, furylglycine, hydroxyphenylglycine, chlorophenylglycine, cyanophenylglycine, alanine, phenylalanine, methionine, serine, tryptophan, valine, leucine, threonine, asparagine, lysine, ⁇ -aminobutyric acid, and other natural or artificial amino acids. They can be either D- or L-isomer, or mixtures thereof including racemic mixtures.
  • Preferable examples are D- ⁇ -phenylglycine, D- ⁇ -(1,4-cyclohexadienyl)glycine, D- ⁇ -(p-hydroxyphenyl)glycine, D- ⁇ -(2-thienyl)glycine, and D- ⁇ -(3-thienyl)glycine.
  • the said ester can be (C 1 to C 10 ) alkyl ester, among which methyl, ethyl, and propyl ester are more preferable.
  • the ester can be N-ammonium salt of said amino acids, for example, mineral acid addition salt at the amino group.
  • Preferable esters are mineral acid addition salts of (C 1 to C 5 ) alkyl ester of said ⁇ -amino acid.
  • Other forms of preferable ester are (C 1 to C 5 ) alkanoic acid salts at the ⁇ -amino group of the said amino acids.
  • the products of this invention are compounds represented by formula I, II, or III above.
  • Representative carboxylates are alkali metal salts, alkaline earth metal salts, and tertiary amine salts; and representative N-ammonium salts are mineral acid salt, and (C 1 to C 10 ) alkanoic acid salts.
  • the products can be in N--(C 1 to C 10 ) acylated forms, in which the acyl group can be alkanoyl, aroyl, carbalkoxy, carbaralkoxy, or like acyl groups.
  • Preferable products include Ampicillin, Cefalexin, Epicillin, Cefradine, Amoxycillin, Cefaloglycin, or their salts.
  • the products prepared by this invention are useful as antibacterials for the treatment of diseases caused by bacterial infections sensitive to the drugs.
  • Several of the products are currently in clinical use.
  • the compounds are also useful for disinfection of animals, plants, or materials, as are known well by those skilled in the art.
  • the methods for their use or application are also known in medical, veterinary, poultry, horticultural, botanical, or other related fields. They are also useful intermediates, e.g., for other antibiotics.
  • the process of this invention is carried out by contacting said amino compound with said ester in the presence of a microorganism belonging to the genus Aphanocladium or Cephalosporium, or its mycelium preparations.
  • the microorganism belonging to the genus Aphanocladium employed in this invention can be known Aphanoclacium aranearum (Petch) Grams. especially, Aphanocladium aranearum MFC-52, (the strain ATCC 20453).
  • microorganisms belonging to the genus Cephalosporium employed in this invention can be known Cephalosporium coremioides Raillo especially Cephalosporium coremioides Raillo, the strain IFO-8579 available to the public.
  • microorganisms can be propagated as follows, to use in this invention:
  • the microorganisms are inoculated in a culture medium and aerobically stirred by shaking culture, stationary culture, or culture under aeration to provide the said mycelium.
  • the culture medium can be conventional ones, and can obtain such carbon and nitrogen sources as bouillon, yeast extract, peptone, corn steep liquor, sugar, organic acid, amino compounds, nitrate, and other carbon and nitrogen sources; such inorganic salts as phosphate, sulfate, and metal salts; and such essential elements necessary for the growth of the fungus as vitamine and amino acids.
  • the incubation can be carried out in an aerobic condition at pH of between about 5 to 8, preferably about 6 to 7, and temperature of between about 20° to about 40° C, for about 3 hours to 10 days.
  • Three respresentative media for the propagation consist of aqueous solution (pH about 7.0) containing (a) glucose (3.5%), peptone (2.0%), corn steep liquor (0.3%); (b) glucose (2.0%), peptone (1.0%), bouillon (0.3%), yeast extract (0.2%), sodium chloride (0.1%); or (c) cane sugar (3.0%), golden protein (1.5%), corn steep liquor (1.5%), DL-methionine (0.5%), and calcium carbonate (0.15%).
  • the mycelium preparation includes all of the preparations available for using penicillin- or cephalosporin-amidase activity of the said microorganisms, for example, washed mycelium obtained by isolating the mycelium propagated as above from the nutrient solution by filtration or centrifugation, followed by washing with water or aqueous solution; mycelium homogenate obtained by crushing the cells of the mycelium; crude or purified enzyme possibly bound on an insoluble material; or extracellular enzyme in the nutrient solution of the propagated medium or its preparation.
  • the propagated medium can also be used for carrying out the reaction of this invention.
  • the substrates can be employed in a form of powder, suspension, solution of hydrophilic organic solvent or aqueous solution.
  • hydrophilic organic solvents are alcohol, acetone, and glycol. These solvents are employed at a concentration which does not inhibit the desired enzymatic reaction.
  • the reaction is carried out in an aqueous solution.
  • Distilled water, buffer solutions, or propagated nutrient media themselves can be used as preferable aqueous solution or aqueous medium for the reaction. Aerobic condition is not essential.
  • peniciilins can be added to inhibit the unfavorable activity.
  • Preferable conditions for the reaction are pH of between about 5 and about 8, a temperature of from about 20° C to about 40° C, and shaking or agitation period for from about 5 to about 50 hours. These conditions vary depending on the sort of starting materials, concentration, sort of microorganism used, character of the culture medium, and working up methods.
  • acid, base, or buffer solution can be added to the reaction mixture when the pH of the medium changes unfavorably during the reaction.
  • the concentration of the starting material is from about 0.1 to about 5%, preferably less than 2%.
  • the mycelium, mycelium preparation or insoluble materials are separated from the reaction mixture by, e.g., filtration, centrifugation, adsorption, denaturation, or the combination thereof; and the products so formed can be separated by various methods such as adsorption, fractional extraction, concentration, deposition, precipitation, or like methods, and can be isolated and purified by conventional methods in the art, e.g., recrystallization, adsorption, chromatography, ion-exchange, reprecipitation, lyophillization, counter-current distribution, and like methods.
  • the hydrogen in the carboxy group can be replaced by another cation to form a salt, or the side chain amino group can form a salt with, e.g., mineral acid, sulfonic acid containing 1 to 10 carbon atoms, or other acids.
  • a medium (100 ml) consisting of an aqueous solution (pH 7.0) containing glucose (3.5%), peptone (2.0%), corn steep liquor (0.3%), is inoculated Aphanocladium aranearum ATCC 20453, and the inoculated medium is cultured with shaking at 28° C for 3 days.
  • the broth is filtered through a cloth to collect mycelium, washed with deionized water, and compressed to remove excess water.
  • This preparation is passed through an ion-exchange resin (Dowex 50W ⁇ 8) column (60 ml) treated with 0.2M citric acid buffer solution (pH 4.5), and the column is washed with the 0.2M citric acid buffer.
  • a small amount of D- ⁇ -phenylglycine methyl ester and 7-aminodeacetoxycephalosporanic acid is recovered from the first fraction.
  • To the next antibiotically active fraction is added 3% by weight of active carbon, and the mixture is filtered after stirring for 30 minutes. The active carbon is collected and eluted with 50% methanol, and the eluate is concentrated under reduced pressure. The residue is treated with methanol and ethyl acetate to give the solid (53 mg) of the crude product.
  • the white powder is recrystallized from a mixture of methanol and ethyl acetate, affording 23.8 mg of 7 ⁇ -(D- ⁇ -phenylglycyl)aminodeacetoxycephalosporanic acid (Cefalexin) monohydrate.
  • 6-aminopenicillanic acid 0.1 g
  • D- ⁇ -phenylglycine methyl ester hydrochloride 0.5 g
  • the product is adsorbed on active carbon after adjusting the pH of the reaction mixture to 6.0 with an aqueous solution of sodium hydroxide.
  • the product is eluted from the active carbon, and recrystallized to give 37.9 mg of sodium 6 ⁇ -(D- ⁇ -phenylglycyl)aminopenicillanate (Sodium ampicillin).
  • 6-aminopenicillanic acid is reacted with D- ⁇ -phenylglycine methyl ester hydrochloride under the condition given in the following table, using Aphanocladium aranearum ATCC 20453.
  • the amount of sodium salt of Ampicillin produced in the reaction mixture is measured by microbiological assay to give the values shown in the same table.
  • 6-aminopenicillanic acid (0.1 g) is reacted with D- ⁇ -(1,4-cyclohexadienyl)glycine methyl ester hydrochloride using Aphanocladium aranearum ATCa 20453 (30° C, 22 hours, pH 6.0).
  • Aphanocladium aranearum ATCa 20453 (30° C, 22 hours, pH 6.0).
  • 6 ⁇ -D- ⁇ -(1,4-cyclohexadienyl)glycylaminopenicillanic acid (Epicillin) (0.064 g) when detected by microbiological assay. Yield: 37.4% (calculated as Ampicillin).
  • 6-aminopenicillanic acid (0.1 g) is reacted with the amino acid derivatives shown in the following table, using Aphanocladium aranearum ATCC 20453 at 28° C for 18 hours to give the corresponding 6 ⁇ -( ⁇ -aminoacyl)aminopenicillanic acid derivatives.
  • the Rf values of each product on thin-layer chromatogram over silica gel developed with a mixture of n-butanol, ethanol, and water (4:1:1 v/v) and the yield determined by microbiological assay are shown in the following table.
  • 6-aminopenicillanic acid (0.1 g) is reacted with D- ⁇ -(p-hydroxyphenyl)glycine methyl ester hydrochloride (1 g) using Aphanocladium aranearum ATCC 20453 at 30° C for 23 hours at pH 6.0.
  • Thin-layer chromatogram of the reaction mixture shows a spot corresponding to 6 ⁇ -D- ⁇ -(p-hydroxyphenyl)glycinamidopenicillanic acid (Amoxycillin).
  • the mycelium of Aphanocladium aranearum ATCC 20453 is homogenated by using 1.5 weights of alumina, diluted with M/15-phosphate buffer (pH 5.0, 6.0, and 7.0) and centrifuged. Ammonium sulfate is added to the supernatant to provide a concentration of 60%, and enzyme fraction is salted out. The obtained precipitate is dissolved in the buffer solution mentioned above, and dialyzed overnight to give crude enzyme solution. This process is carried out at a temperature of 0° to 4° C.
  • the enzyme solution (1 ml) is reacted on 7-aminodeacetoxycephalosporanic acid and D- ⁇ -phenylglycine methyl ester hydrochloride at 37° C.
  • the amount of the obtained Cefalexin in the reaction mixture determined by microbiological assay
  • the crude enzyme solution obtained by the method of Example 12 (1 ml) is reacted on 6-aminopenicillanic acid and D- ⁇ -phenylglycine methyl ester hydrochloride at 37° C.
  • the amount of ampicillin produced in the reaction mixture is measured by microbiological assay, and the results are shown in the following table.
  • a sterilized medium 100 ml consisting of aqueous solution (pH 7.0) containing glucose (3.5%), peptone (2.0%), and corn steep liquor (0.3%), is inoculated Cephalosporium coremioides IFO-8579, and the medium is shaken at 28° C for 3 days. The broth is centrifuged to collect the mycelia, which is washed with deionized water.
  • the wet mycelium so obtained is suspended in M/30-phosphate buffer (pH 6.0), containing 7-aminodeacetoxycephalosporanic acid and D- ⁇ -phenylglycine methyl ester hydrochloride (0.4 g), at 28° C for 24 hours.
  • the amount of Cefalexin formed in the reaction mixture is 0.095 g when determined by microbiological assay.
  • 6-aminopenicillanic acid is reacted with D- ⁇ -phenylglycine methyl ester hydrochloride using the mycelium obtained in the procedure of Example 15 to produce 0.08 g of Ampicillin when determined by microbiological assay.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Penicillin or cephalosporin antibiotics represented by following formula: ##STR1## where ##STR2## is an acyl group derived from an α-amino acid, N-ammonium salt of α-amino acid, or N--(C1 to C10) acyl-α-amino acid; COOM is carboxy or carboxylate salt group!
Are prepared by treating an amino compound selected from a group consisting of 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid, and their salts with an ester represented by following formula:
RCOOR.sup.1
where ##STR3## is as defined above and R1 is a (C1 to C10) alkyl group! BY ENZYMATIC ACYLATION EFFECTED WITH MYCELIUM OR MYCELIUM PREPARATION FROM A MICROORGANISM BELONGING TO GENUS Aphanocladium or Cephalosporium.

Description

This invention relates to a process for preparing penicillin or cephalosporin antibiotics represented by the following formula: ##STR4## where ##STR5## is an acyl group derived from an α-amino acid, N-ammonium salt of α-amino acid, or N-(C1 to C10) acyl-α-amino acid; COOM is a carboxy or carboxylate salt group!
By treating an amino compound selected from the group consisting of 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid and their salts, with an ester represented by the following formula:
RCOOR.sup.1
where ##STR6## is as defined above and R1 is a (C1 to C10) alkyl group! by enzymatic acylation effected with mycelium or mycelium preparation from a microorganism belonging to genus Aphanocladium or Cephalosporium.
Several penicillins and cephalosporins have been reported to be synthesized by enzymatic acylation to form α-aminoacyl side chains South Africa Pat. No. 62/3870; U.S. Pat. No. 3,152,050; German patent application Nos. 1,945,607 and 2,050,982; Dutch patent application No. 7,117,613; French Pat. No. 2,188,608; Belgian Pat. No. 808,288; Japanese patent application (Publication) Nos. 47-25,388, 48-35,090, 49-13,393, and 49-62,695; and other publications!.
It has now been found that this acylation can also take place by the action of fungal microorganisms belonging to genus Aphanocladium or Cephalosporium, and the action is, contrary to common bacterial actions, irreversible in nature.
Among said amino compounds are 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid, and their salts. Illustrative of the salts are those at the carboxyl group, including such salts as alkali metal salts, alkaline earth metal salts, and tertiary amine salts; and those at the amino group, including such mineral acid salts as hydrochloride, hydrogen sulfate, and hydrogen carbonate. Preferable salts are alkali metal salts at the carboxy group.
The said amino acid can be glycine, phenylglycine, cyclohexadienylglycine, cyclohexylglycine, thienylglycine, furylglycine, hydroxyphenylglycine, chlorophenylglycine, cyanophenylglycine, alanine, phenylalanine, methionine, serine, tryptophan, valine, leucine, threonine, asparagine, lysine, α-aminobutyric acid, and other natural or artificial amino acids. They can be either D- or L-isomer, or mixtures thereof including racemic mixtures. Preferable examples are D-α-phenylglycine, D-α-(1,4-cyclohexadienyl)glycine, D-α-(p-hydroxyphenyl)glycine, D-α-(2-thienyl)glycine, and D-α-(3-thienyl)glycine.
The said ester can be (C1 to C10) alkyl ester, among which methyl, ethyl, and propyl ester are more preferable. The ester can be N-ammonium salt of said amino acids, for example, mineral acid addition salt at the amino group.
Preferable esters are mineral acid addition salts of (C1 to C5) alkyl ester of said α-amino acid. Other forms of preferable ester are (C1 to C5) alkanoic acid salts at the α-amino group of the said amino acids.
The products of this invention are compounds represented by formula I, II, or III above. Representative carboxylates are alkali metal salts, alkaline earth metal salts, and tertiary amine salts; and representative N-ammonium salts are mineral acid salt, and (C1 to C10) alkanoic acid salts. The products can be in N--(C1 to C10) acylated forms, in which the acyl group can be alkanoyl, aroyl, carbalkoxy, carbaralkoxy, or like acyl groups.
Preferable products include Ampicillin, Cefalexin, Epicillin, Cefradine, Amoxycillin, Cefaloglycin, or their salts.
The products prepared by this invention are useful as antibacterials for the treatment of diseases caused by bacterial infections sensitive to the drugs. Several of the products are currently in clinical use. The compounds are also useful for disinfection of animals, plants, or materials, as are known well by those skilled in the art. The methods for their use or application are also known in medical, veterinary, poultry, horticultural, botanical, or other related fields. They are also useful intermediates, e.g., for other antibiotics.
The process of this invention is carried out by contacting said amino compound with said ester in the presence of a microorganism belonging to the genus Aphanocladium or Cephalosporium, or its mycelium preparations.
The microorganism belonging to the genus Aphanocladium employed in this invention can be known Aphanoclacium aranearum (Petch) Grams. especially, Aphanocladium aranearum MFC-52, (the strain ATCC 20453).
The microorganisms belonging to the genus Cephalosporium employed in this invention can be known Cephalosporium coremioides Raillo especially Cephalosporium coremioides Raillo, the strain IFO-8579 available to the public.
All natural and artificial variants, mutants or adapted strains derived from the microorganisms belonging to genus Aphanocladium or Cephalosporium showing the desired enzymatic activity are included in the scope of the microorganisms suitable for use in this invention.
These microorganisms can be propagated as follows, to use in this invention: The microorganisms are inoculated in a culture medium and aerobically stirred by shaking culture, stationary culture, or culture under aeration to provide the said mycelium. The culture medium can be conventional ones, and can obtain such carbon and nitrogen sources as bouillon, yeast extract, peptone, corn steep liquor, sugar, organic acid, amino compounds, nitrate, and other carbon and nitrogen sources; such inorganic salts as phosphate, sulfate, and metal salts; and such essential elements necessary for the growth of the fungus as vitamine and amino acids. In particular, the incubation can be carried out in an aerobic condition at pH of between about 5 to 8, preferably about 6 to 7, and temperature of between about 20° to about 40° C, for about 3 hours to 10 days. Three respresentative media for the propagation consist of aqueous solution (pH about 7.0) containing (a) glucose (3.5%), peptone (2.0%), corn steep liquor (0.3%); (b) glucose (2.0%), peptone (1.0%), bouillon (0.3%), yeast extract (0.2%), sodium chloride (0.1%); or (c) cane sugar (3.0%), golden protein (1.5%), corn steep liquor (1.5%), DL-methionine (0.5%), and calcium carbonate (0.15%).
The mycelium preparation includes all of the preparations available for using penicillin- or cephalosporin-amidase activity of the said microorganisms, for example, washed mycelium obtained by isolating the mycelium propagated as above from the nutrient solution by filtration or centrifugation, followed by washing with water or aqueous solution; mycelium homogenate obtained by crushing the cells of the mycelium; crude or purified enzyme possibly bound on an insoluble material; or extracellular enzyme in the nutrient solution of the propagated medium or its preparation. The propagated medium can also be used for carrying out the reaction of this invention.
The substrates can be employed in a form of powder, suspension, solution of hydrophilic organic solvent or aqueous solution. Preferable hydrophilic organic solvents are alcohol, acetone, and glycol. These solvents are employed at a concentration which does not inhibit the desired enzymatic reaction.
The reaction is carried out in an aqueous solution. Distilled water, buffer solutions, or propagated nutrient media themselves can be used as preferable aqueous solution or aqueous medium for the reaction. Aerobic condition is not essential. When the microorganisms contain 62 -lactamase, peniciilins can be added to inhibit the unfavorable activity. Preferable conditions for the reaction are pH of between about 5 and about 8, a temperature of from about 20° C to about 40° C, and shaking or agitation period for from about 5 to about 50 hours. These conditions vary depending on the sort of starting materials, concentration, sort of microorganism used, character of the culture medium, and working up methods. If desired, acid, base, or buffer solution can be added to the reaction mixture when the pH of the medium changes unfavorably during the reaction. The concentration of the starting material is from about 0.1 to about 5%, preferably less than 2%.
After the reaction, the mycelium, mycelium preparation or insoluble materials are separated from the reaction mixture by, e.g., filtration, centrifugation, adsorption, denaturation, or the combination thereof; and the products so formed can be separated by various methods such as adsorption, fractional extraction, concentration, deposition, precipitation, or like methods, and can be isolated and purified by conventional methods in the art, e.g., recrystallization, adsorption, chromatography, ion-exchange, reprecipitation, lyophillization, counter-current distribution, and like methods. During the working up, the hydrogen in the carboxy group can be replaced by another cation to form a salt, or the side chain amino group can form a salt with, e.g., mineral acid, sulfonic acid containing 1 to 10 carbon atoms, or other acids.
The following examples are given to explain more detailed embodiments of this invention, but not to limit the scope thereof.
EXAMPLE 1
In a medium (100 ml) consisting of an aqueous solution (pH 7.0) containing glucose (3.5%), peptone (2.0%), corn steep liquor (0.3%), is inoculated Aphanocladium aranearum ATCC 20453, and the inoculated medium is cultured with shaking at 28° C for 3 days. The broth is filtered through a cloth to collect mycelium, washed with deionized water, and compressed to remove excess water.
About 9 g of the wet mycelium so obtained is suspended in deionized water (100 ml) containing 7-aminodeacetoxycephalosporanic acid (0.1 g) and D-α-phenylglycine methyl ester hydrochloride (0.5 g). The suspension is adjusted to pH 6.0 with an aqueous solution of 1N-sodium carbonate, and stirred at 30° C for 16 hours, while the pH is maintained at 6.0. The suspension is then filtered to remove mycelium, and stored at 0° C overnight. After filtering off the crystallized D-α-phenylglycine, the filtrate is adjusted to pH 4.0 with 1N-hydrochloric acid. This preparation is passed through an ion-exchange resin (Dowex 50W × 8) column (60 ml) treated with 0.2M citric acid buffer solution (pH 4.5), and the column is washed with the 0.2M citric acid buffer. A small amount of D-α-phenylglycine methyl ester and 7-aminodeacetoxycephalosporanic acid is recovered from the first fraction. To the next antibiotically active fraction is added 3% by weight of active carbon, and the mixture is filtered after stirring for 30 minutes. The active carbon is collected and eluted with 50% methanol, and the eluate is concentrated under reduced pressure. The residue is treated with methanol and ethyl acetate to give the solid (53 mg) of the crude product.
The white powder is recrystallized from a mixture of methanol and ethyl acetate, affording 23.8 mg of 7β-(D-α-phenylglycyl)aminodeacetoxycephalosporanic acid (Cefalexin) monohydrate.
m.p. 185°-190° C (decomp.)
I.r. νmax Nujol 1763, 1690, 1590 cm-1.
EXAMPLE 2
Under the same condition as described in Example 1, 6-aminopenicillanic acid (0.1 g) is reacted with D-α-phenylglycine methyl ester hydrochloride (0.5 g) using Aphanocladium aranearum ATCC 20453. The product is adsorbed on active carbon after adjusting the pH of the reaction mixture to 6.0 with an aqueous solution of sodium hydroxide. Following the procedure set forth in Example 1, the product is eluted from the active carbon, and recrystallized to give 37.9 mg of sodium 6β-(D-α-phenylglycyl)aminopenicillanate (Sodium ampicillin).
m.p. 221°-226° C (decomp.)
I.r. νmax Nujol 1770, 1691, 1600 cm-1.
EXAMPLE 3
Under the condition similar to that described in Example 1, 7-aminodeacetoxycephalosporanic acid (0.1 g) is reacted with D-α-phenylglycine methyl ester hydrochloride using Aphanocladium aranearum ATCC 20453 (30° C, 16 hours, pH 6.0). The paper disk microbiological assay of the reaction mixture using Bacillus subtilis PCI-219, shows that 0.118 g of Cefalexin is produced. Yield: 72.8%.
EXAMPLE 4
Under the condition similar to that described in Example 1, 7-aminodeacetoxycephalosporanic acid (0.25 g) is reacted with D-α-phenylglycine hydrochloride methyl ester using Aphanocladium aranearum ATCC 20453 (30° C, 23 hours, pH 6.0). Cefalexin (0.292 g) is found in the reaction mixture by microbiological assay. Yield: 71.9%.
EXAMPLE 5
Under the condition similar to that of Example 1, 7-aminodeacetoxycephalosporanic acid (0.3 l g) is reacted with D-α-phenylglycine methyl ester hydrochloride using Aphanocladium aranearum ATCC 20453 (30° C, 19 hours, pH 6.0). Cefalexin (0.338 g) is found in the reaction mixture by microbiological assay. Yield: 69.6%.
EXAMPLE 6
Following the procedure set forth in Example 1, 6-aminopenicillanic acid is reacted with D-α-phenylglycine methyl ester hydrochloride under the condition given in the following table, using Aphanocladium aranearum ATCC 20453. The amount of sodium salt of Ampicillin produced in the reaction mixture is measured by microbiological assay to give the values shown in the same table.
______________________________________
Amount of Substrate (g/dl)
                Reaction  Yield of Ampicillin
6-APA.sup.1)
         PGM.sup.2) Time (hr) (g/dl)  (%)
______________________________________
0.1      1.0        17        0.1304  75.9
0.2      2.0        16        0.2380  69.3
0.3      3.0        15        0.4460  86.6
______________________________________
 (30° C, pH 6.0)
 .sup.1) 6-aminopenicillanic acid
 .sup.2) D-α-phenylglycine methyl ester hydrochloride
EXAMPLE 7
Under the condition similar to that of Example 1, 7-aminodeacetoxycephalosporanic acid (0.1 g) is reacted with D-α-(1,4-cyclohexadienyl)glycine methyl ester hydrochloride using Aphanocladium aranearum ATCC 20453 (30° C, 22 hours, pH 6.0). In the reaction mixture is found 7β- D-α-(1,4-cyclohexadienyl)-glycylaminodeacetoxycephalosporanic acid (Cephradin, Rf: 0.35, 0.109 g) when detected by microbiological assay. Yield: 67.3% (Calculated as Cefalexin).
EXAMPLE 8
Under the condition similar to that of Example 7, 6-aminopenicillanic acid (0.1 g) is reacted with D-α-(1,4-cyclohexadienyl)glycine methyl ester hydrochloride using Aphanocladium aranearum ATCa 20453 (30° C, 22 hours, pH 6.0). In the reaction mixture is found 6β-D-α-(1,4-cyclohexadienyl)glycylaminopenicillanic acid (Epicillin) (0.064 g) when detected by microbiological assay. Yield: 37.4% (calculated as Ampicillin).
EXAMPLE 9
Under the condition similar to that of Example 1, 7-aminodeacetoxycephalosporanic acid (0.1 g) is reacted with amino acid derivatives shown in the following table, using Aphanocladium aranearum ATCC 20453 at 28° C for 18 hours to give the corresponding 7β-(αaminoacyl)aminodeacetoxycephalosporanic acid derivatives. The Rf values of each product on thin-layer chromatogram over silica gel are also shown in the table (developed with a mixture of ethyl acetate, acetic acid, and water (3:1:1 v/v)).
______________________________________
Starting amino acid derivatives
                      Rf of products
______________________________________
DL-methionine methyl ester
                      0.57
DL-alanine methyl ester
                      --
DL-phenylalanine methyl ester
                      --
DL-serine methyl ester
                      --
DL-tryptophan methyl ester
                      0.39
DL-valine methyl ester
                      --
DL-α-aminobutyric acid methyl ester
                      --
α-N-benzoyl-DL-alanine methyl ester
                      0.84
α-N-carbobenzoxy-D-phenylglycine
                      0.53
methyl ester
______________________________________
EXAMPLE 10
Under the conditions similar to that of Example 9, 6-aminopenicillanic acid (0.1 g) is reacted with the amino acid derivatives shown in the following table, using Aphanocladium aranearum ATCC 20453 at 28° C for 18 hours to give the corresponding 6β-(α-aminoacyl)aminopenicillanic acid derivatives. The Rf values of each product on thin-layer chromatogram over silica gel developed with a mixture of n-butanol, ethanol, and water (4:1:1 v/v) and the yield determined by microbiological assay are shown in the following table.
______________________________________
                Production (γ/ml)
Starting amino acid
                calculated as  Rf of
derivatives     Ampicillin     Products
______________________________________
DL-methionine methyl
                13             0.27
ester
DL-alanine methyl
                31             --
ester
DL-phenylalanine
                +              --
methyl ester
DL-serine methyl ester
                25             0.32
DL-tryptophan methyl
                16             --
ester
DL-valine methyl ester
                36             --
DL-α-aminobutyric acid
                63             0.13
methyl
α-N-benzoyl-DL-alanine
                108            0.35
methyl ester
α-N-carbobenzoxy-D-phe-
                22             0.48
nyglycine methyl ester
______________________________________
EXAMPLE 11
Under the condition similar to that of Example 1, 6-aminopenicillanic acid (0.1 g) is reacted with D-α-(p-hydroxyphenyl)glycine methyl ester hydrochloride (1 g) using Aphanocladium aranearum ATCC 20453 at 30° C for 23 hours at pH 6.0. Thin-layer chromatogram of the reaction mixture shows a spot corresponding to 6β-D-α-(p-hydroxyphenyl)glycinamidopenicillanic acid (Amoxycillin).
EXAMPLE 12
The mycelium of Aphanocladium aranearum ATCC 20453 is homogenated by using 1.5 weights of alumina, diluted with M/15-phosphate buffer (pH 5.0, 6.0, and 7.0) and centrifuged. Ammonium sulfate is added to the supernatant to provide a concentration of 60%, and enzyme fraction is salted out. The obtained precipitate is dissolved in the buffer solution mentioned above, and dialyzed overnight to give crude enzyme solution. This process is carried out at a temperature of 0° to 4° C.
The enzyme solution (1 ml) is reacted on 7-aminodeacetoxycephalosporanic acid and D-α-phenylglycine methyl ester hydrochloride at 37° C. The amount of the obtained Cefalexin in the reaction mixture determined by microbiological assay
______________________________________
Amount of Sub-
            Concentration
                        pH of   Produced
strate (mg/ml)
            of enzyme pro-
                        me-     Cefalexin (γ/ml)
7-ADCA.sup.1)
        PGM.sup.2)
                tein (mg/ml)
                            dium  1 hr. 3 hrs.
______________________________________
1.0    2.5     5.0         5.0    82     69
1.0    2.5     5.0         6.0   316    500
1.0    2.5     5.0         7.0   177    145
1.0    5.0     5.0         7.0   180    170
3.0    7.5     2.0         6.0   393    643
1.0    2.5     2.0         6.0   205    282
1.0    5.0     2.0         6.0   247    429
______________________________________
 .sup.1) 7-aminodeacetoxycephalosporanic acid
 .sup.2) D-α-phenylglycine methyl ester hydrochloride
EXAMPLE 13
The crude enzyme solution obtained by the method of Example 12 (1 ml) is reacted on 6-aminopenicillanic acid and D-α-phenylglycine methyl ester hydrochloride at 37° C. The amount of ampicillin produced in the reaction mixture is measured by microbiological assay, and the results are shown in the following table.
______________________________________
Amount of Sub-
           Concentration
                       pH of   Produced
strate (mg/ml)
           of enzyme pro-
                       me-     Ampicillin (γ/ml)
6-APA.sup.1)
       PGM.sup.2)
               tein (mg/ml)
                           dium  1 hr.  3 hrs.
______________________________________
1.0    2.5     5.0         5.0   126    126
1.0    2.5     5.0         6.0   465    540
1.0    2.5     5.0         7.0   224    255
1.0    5.0     5.0         7.0   210    221
0.5    2.5     2.0         6.0   191    264
3.0    7.5     2.0         6.0   890    1370
1.0    2.5     2.0         6.0   300    475
1.0    5.0     2.0         6.0   379    695
______________________________________
 .sup.1) 6-aminopenicillanic acid
 .sup.2) D-α-phenylglycine methyl ester hydrochloride
EXAMPLE 14
Under the condition similar to that of Example 1, 7-aminocephalosporanic acid (0.25%) is reacted with D-α-phenylglycine methyl ester hyrochloride (2.5 g) using Aphanocladium aranearum ATCC 20453 (30° C, 23 hours, pH 6.0). Spots of cephaloglycine and deacetylcephaloglycine are shown on thin-layer chromatogram, and the amount of Cefaloglycin formed is 0.072 g when determined by microbiological assay.
EXAMPLE 15
To a sterilized medium (100 ml) consisting of aqueous solution (pH 7.0) containing glucose (3.5%), peptone (2.0%), and corn steep liquor (0.3%), is inoculated Cephalosporium coremioides IFO-8579, and the medium is shaken at 28° C for 3 days. The broth is centrifuged to collect the mycelia, which is washed with deionized water.
The wet mycelium so obtained is suspended in M/30-phosphate buffer (pH 6.0), containing 7-aminodeacetoxycephalosporanic acid and D-α-phenylglycine methyl ester hydrochloride (0.4 g), at 28° C for 24 hours. The amount of Cefalexin formed in the reaction mixture is 0.095 g when determined by microbiological assay.
EXAMPLE 16
Under the condition similar to that of Example 15, 6-aminopenicillanic acid is reacted with D-α-phenylglycine methyl ester hydrochloride using the mycelium obtained in the procedure of Example 15 to produce 0.08 g of Ampicillin when determined by microbiological assay.

Claims (11)

What we claim is:
1. A process for preparing a penicillin or cephalosporin antibiotic of the formula ##STR7## wherein ##STR8## is an acyl group derived from an α-amino acid, an N- ammonium salt of an α-amino acid or an N--(C1 to C10) acyl-α-amino acid and COOM is carboxy or a carboxylate salt group, which comprises reacting an amino compound selected from the group consisting of 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid and salts thereof with an ester of the formula ##STR9## wherein ##STR10## is as defined above and R1 is a (C1 to C10) alkyl group, by enzymatic acylation effected with mycelium or mycelium preparation from a microorganism belonging to the genus Aphanocladium or to Cephalosporium caremoioides Radilla.
2. A process according to claim 1, wherein the amino compound is selected from the group consisting of 6-aminopenicillanic acid, b 7-aminocephalosporanic acid, 7-aminodeacetoxycephalosporanic acid and their alkali metal salts.
3. A process according to claim 1, wherein the α-amino acid is selected from the group consiting of glycine, phenylglycine, cyclohexadienylglycine, cyclohexylglycine, thienylglycine, furylglycine, hydroxyphenylglycine, chlorophenylglycine, cyanophenylglycine, alanine, phenylalanine, methionine, serine tryptophan, valine, leucine, threonine, asparagine, lysine, α-aminobutyric acid, and their N-benzoyl-or N-carbobenzoxy derivatives.
4. A process according to claim 1, wherein the α-amino acid is selected from D-α-phenylglycine, D-α-(1,4-cyclohexadienyl)glycine, D-α-(p-hydroxyphenyl)glycine, D-α-(2-thienyl)glycine, and D-α-(3-thienyl)glycine.
5. A process according to claim 1, wherein the ester is a (C1 to C5) alkyl ester of a mineral acid addition salt of said α-amino acid.
6. A process according to claim 1, wherein the microorganism is Aphanocladium aranearum (Petch) Grams., ATCC 20453.
7. A process according to claim 1, wherein the microorganism is Cephalosporium coremioides Raillo., IFO-8579.
8. A process according to claim 1, wherein the mycelium preparation is a washed mycelium.
9. A process according to claim 1, wherein the mycelium preparation is a crude or purified enzyme.
10. A process according to claim 1, wherein the reaction is carried out at a pH from of 5.0 to 8.0.
11. A process according to claim 1, wherein said penicillin or cephalosporin antibiotic is Ampicillin, Epicillin, Amoxycillin, Cefalexin, Cefradine, Cefaloglycin or a salt thereof.
US05/686,219 1975-05-14 1976-05-12 Enzymatic acylation to afford β-lactam antibiotics Expired - Lifetime US4073687A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP50057844A JPS51133488A (en) 1975-05-14 1975-05-14 Process for producing antibiotics enzymatically
JA50-57844 1975-05-14

Publications (1)

Publication Number Publication Date
US4073687A true US4073687A (en) 1978-02-14

Family

ID=13067273

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/686,219 Expired - Lifetime US4073687A (en) 1975-05-14 1976-05-12 Enzymatic acylation to afford β-lactam antibiotics

Country Status (8)

Country Link
US (1) US4073687A (en)
JP (1) JPS51133488A (en)
CA (1) CA1049431A (en)
CH (1) CH629534A5 (en)
DE (1) DE2621618A1 (en)
FR (1) FR2310757A1 (en)
GB (1) GB1544844A (en)
NL (1) NL7605138A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340672A (en) * 1979-09-19 1982-07-20 Shionogi & Co., Ltd. Enzymatic synthesis of β-lactam antibacterials
WO2005003367A3 (en) * 2003-07-03 2005-05-26 Dsm Ip Assets Bv Process for the preparation of cephradine
CN100507000C (en) * 2003-07-03 2009-07-01 帝斯曼知识产权资产管理有限公司 The method for preparing cephradine

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926548T2 (en) * 1988-04-26 1996-09-26 Gist Brocades Nv Process for the enzymatic production of beta-lactams
US20140200342A1 (en) 2011-06-23 2014-07-17 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for preparing 3'-thiosubstituted cephalosporins employing a pencillin g acylase
CN103635586A (en) 2011-06-23 2014-03-12 中化帝斯曼制药有限公司荷兰公司 Crystalline cefoperazone intermediate, preparing method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3761354A (en) * 1972-03-27 1973-09-25 Toyo Jozo Kk Process for the production of cephalexin
US3763000A (en) * 1971-08-20 1973-10-02 Toyo Jozo Kk Enzymatic production of cephalexin
US3816253A (en) * 1971-04-02 1974-06-11 Takeda Chemical Industries Ltd Method for the production of cephalosporins
US3862004A (en) * 1972-12-06 1975-01-21 Takeda Chemical Industries Ltd Method for production of cephalosporins
US3962036A (en) * 1973-12-20 1976-06-08 Ciba-Geigy Corporation Process for the manufacture of 7-amino-cephalosporanic acid-type compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816253A (en) * 1971-04-02 1974-06-11 Takeda Chemical Industries Ltd Method for the production of cephalosporins
US3763000A (en) * 1971-08-20 1973-10-02 Toyo Jozo Kk Enzymatic production of cephalexin
US3761354A (en) * 1972-03-27 1973-09-25 Toyo Jozo Kk Process for the production of cephalexin
US3862004A (en) * 1972-12-06 1975-01-21 Takeda Chemical Industries Ltd Method for production of cephalosporins
US3962036A (en) * 1973-12-20 1976-06-08 Ciba-Geigy Corporation Process for the manufacture of 7-amino-cephalosporanic acid-type compounds

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340672A (en) * 1979-09-19 1982-07-20 Shionogi & Co., Ltd. Enzymatic synthesis of β-lactam antibacterials
WO2005003367A3 (en) * 2003-07-03 2005-05-26 Dsm Ip Assets Bv Process for the preparation of cephradine
US20060189802A1 (en) * 2003-07-03 2006-08-24 Dennis Heemskerk Process for the preparation of cephradine
CN100507000C (en) * 2003-07-03 2009-07-01 帝斯曼知识产权资产管理有限公司 The method for preparing cephradine
US7588913B2 (en) 2003-07-03 2009-09-15 Dsm Ip Assets B.V. Process for the preparation of cephradine

Also Published As

Publication number Publication date
CA1049431A (en) 1979-02-27
GB1544844A (en) 1979-04-25
JPS51133488A (en) 1976-11-19
NL7605138A (en) 1976-11-16
FR2310757B1 (en) 1980-10-24
FR2310757A1 (en) 1976-12-10
DE2621618A1 (en) 1976-11-25
CH629534A5 (en) 1982-04-30

Similar Documents

Publication Publication Date Title
US2941995A (en) Recovery of solid 6-aminopenicillanic acid
US4529720A (en) Antibiotic from Streptomyces clavulicerus
CZ381392A3 (en) Process for preparing beta-lactams
US3945888A (en) Method for the production of cephalosporins
US4510246A (en) Isolation of cyclase, epimerase and a ring expansion enzyme for producing unnatural cephalosporins
US4073687A (en) Enzymatic acylation to afford β-lactam antibiotics
US3528965A (en) Penicillin ester process and products
DE2216113C2 (en) Process for the production of cephalosporins
DE69315634T2 (en) Process for acylation of the 7-amino group of the cephalosporin ring
US3862004A (en) Method for production of cephalosporins
US4340672A (en) Enzymatic synthesis of β-lactam antibacterials
US4141790A (en) Process for the preparation of 7-amino-cephem compounds using mold fungi
US4248967A (en) Enzymic complexes adapted to convert racemic hydantoins into optically active aminoacids, and their applications
US4302541A (en) Process of producing optically active cephalosporin analogs by enzyme selective deacylation
US3769169A (en) Fermentation process
US4847200A (en) Biosynthesis of unnatural cephalosporins
US4135978A (en) Production of n-acyl-thienamycins
US3975235A (en) Process for the production of cephamycin type antibiotic substances
US3905868A (en) Enzymatic deacylation of benzyl- and phenoxymethylpenicillin tetrazoles
US3749642A (en) Method for the production of aminopenicillins
US4316958A (en) Process for producing optically active cephalosporin analogs
US3925155A (en) Preparation of 6-aminopenicillanic acid 1-oxide
CA1055415A (en) Enzymatic production of 7-(3-alkanesulfonamido phenyl-d-glycinamido)-3-desacetoxy cephalosporanic acid
US3576797A (en) Biologically active derivatives of 6-aminopenicillanic acid and their production
US4332896A (en) Process for producing cephalosporin analogs